Table 9.
Effects of synthesized compounds on the MCF-7 cell cycle.
| Comp. | Cell Cycle (%) | |||||
|---|---|---|---|---|---|---|
| Stage | G0/G1 a,b | S c | G2/M d,e | |||
| Conc. (nM) | 0.1 (1) f | 1 (10) | 0.1 (1) f | 1 (10) | 0.1 (1) f | 1 (10) |
| 3DPQ-1 | 72.62 ± 2.47 *,†,‡,§ | 75.08 ± 2.13 *,†,‡,§ | 9.98 ± 1.65 *,†,‡,§ | 10.69 ± 1.42 *,†,‡,§ | 17.40 ± 3.63 *,†,‡,§ | 14.24 ± 2.54 *,†,‡,§ |
| 3DPQ-2 | 73.64 ± 5.32 *,†,‡,§ | 76.10 ± 1.43 *,†,‡,§ | 11.88 ± 0.87 *,†,‡,§ | 12.59 ± 1.57 *,†,‡,§ | 14.48 ± 2.54 *,†,‡,§ | 11.32 ± 3.25 *,†,‡,§ |
| 3DPQ-3 | 72.99 ± 1.32 *,†,‡,§ | 75.45 ± 1.53 *,†,‡,§ | 8.98 ± 1.64 *,†,‡,§ | 9.69 ± 0.94 *,†,‡,§ | 18.03 ± 1.65 *,†,‡,§ | 14.87 ± 2.43 *,†,‡,§ |
| 3DPQ-4 | 77.78 ± 3.54 *,†,‡,§ | 80.24 ± 2.53 *,†,‡,§ | 7.20 ± 2.88 *,†,‡,§ | 7.91 ± 0.1.54 *,†,‡,§ | 15.02 ± 4.23 *,†,‡,§ | 11.86 ± 3.43 *,†,‡,§ |
| 3DPQ-5 | 71.78 ± 0.67 *,†,‡,§ | 74.24 ± 2.15 *,†,‡,§ | 9.21 ± 1.95 *,†,‡,§ | 9.92 ± 0.76 *,†,‡,§ | 19.01 ± 3.55 *,†,‡,§ | 15.85 ± 4.43 *,†,‡,§ |
| 3DPQ-6 | 70.52 ± 1.53 *,†,‡,§ | 71.98 ± 2.44 *,†,‡,§ | 13.27 ± 2.64 *,†,‡,§ | 13.98 ± 1.33 *,†,‡,§ | 16.21 ± 3.25 *,†,‡,§ | 14.05 ± 2.43 *,†,‡,§ |
| 3DPQ-7 | 73.25 ± 2.54 *,†,‡,§ | 75.71 ± 1.43 *,†,‡,§ | 14.06 ± 1.58 *,†,‡,§ | 14.77 ± 1.46 *,†,‡,§ | 12.69 ± 2.64 *,†,‡,§ | 9.53 ± 3.54 *,†,‡,§ |
| 3DPQ-8 | 72.39 ± 1.43 *,†,‡,§ | 74.85 ± 2.54 *,†,‡,§ | 12.50 ± 1.22 *,†,‡,§ | 13.21 ± 2.15 *,†,‡,§ | 15.11 ± 2.56 *,†,‡,§ | 11.95 ± 2.45 *,†,‡,§ |
| 3DPQ-9 | 71.47 ± 0.99 *,†,‡,§ | 75.93 ± 152 *,†,‡,§ | 12.97 ± 1.65 *,†,‡,§ | 13.68 ± 1.74 *,†,‡,§ | 15.56 ± 2.65 *,†,‡,§ | 10.40 ± 3.54 *,†,‡,§ |
| 3DPQ-10 | 71.96 ± 1.43 *,†,‡,§ | 74.42 ± 2.12 *,†,‡,§ | 11.96 ± 2.41 *,†,‡,§ | 12.67 ± 2.46 *,†,‡,§ | 16.08 ± 1.56 *,†,‡,§ | 12.92 ± 4.32 *,†,‡,§ |
| 3DPQ-11 | 72.53 ± 0.47 *,†,‡,§ | 74.99 ± 2.54 *,†,‡,§ | 13.31 ± 1.66 *,†,‡,§ | 14.02 ± 1.43 *,†,‡,§ | 14.16 ± 2.13 *,†,‡,§ | 11.00 ± 3.43 *,†,‡,§ |
| 3DPQ-12 | 77.83 ± 0.92 *,†,‡,§ | 80.29 ± 1.24 *,†,‡,§ | 16.96 ± 1.23 *,†,‡,§ | 17.67 ± 1.32 *,†,‡,§ | 5.21 ± 2.54 *,†,‡,§ | 2.05 ± 1.43 *,†,‡,§ |
| E2 g | 17.34 ± 0.35 *,‡,§ | 25.34 ± 0.36 *,‡,§ | 28.15 ± 0.52 *,‡,§ | 29.52 ± 0.46 *,‡,§ | 54.51 ± 0.57 *,‡,§ | 45.14 ± 0.33 *,‡,§ |
| 4-OTH. h | 57.22 ± 0.37 *,†,§ | 63.26 ± 0.41 *,†,§ | 18.76 ± 0.41 *,†,§ | 21.14 ± 0.25 *,†,§ | 24.02 ± 0.53 *,,†§ | 15.60 ± 0.15 *,†,§ |
| Ral. i | 59.14 ± 0.54 *,†,‡ | 66.52 ± 0.56 *,†,‡ | 15.83 ± 0.53 *,†,‡ | 16.37 ± 0.46 *,†,‡ | 25.03 ± 0.35 *,†,‡ | 17.11 ± 0.46 *,†,‡ |
| Control j | 32.21 ± 0.45 | 34.97 ± 0.53 | 32.82 ± 0.35 | |||
a Cell resting states: G0—a cell has left the cycle and has stopped dividing; b Cell interphase (i.e., synthesis) state: G1—cells size increase (preparation for DNA synthesis); c Cell interphase (i.e., synthesis) state: S DNA replication; d Cell interphase (i.e., synthesis) state: G2—the gap between DNA synthesis and mitosis, in which the cell continues to grow; e Cell division states: M cell growth stops, division occurs; f The compounds concentration in nM administered to MCF-7 cells (all the compounds except 3DPQ-5, 3DPQ-6, and 3DPQ-8 have been re-administered in concentrations of 0.1 and 1 nM; for the marked compounds, the concentrations were 1 and 10 nM; Values: mean ± standard deviation. g 17β-estradiol; h 4-hydroxytamoxifen; i raloxifene; j 0.9% NaCl. * p < 0.05 when compared with control group; † p < 0.05 when compared with E2; ‡ p < 0.05 when compared with 4-OTH; § p < 0.05 when compared with Ral.